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i. 
The aim of this study was to detect differences in maximal response and position of the concentration-response 
curves to niethacholine between asthmatics and subjects with allergic rhinitis. 
A total of 228 adults (107 mild asthmatics, 96 allergic rhinitics and 25 healthy control subjects) were challenged 
with methacholine. The test was interrupted when FEV, dropped by more than 40% or when the highest 
concentration of methacholine (200 mg ml ~ ‘) had been administered. Concentration-response curves were 
characterized by their PC,, (concentration of methacholine that produced 20% fall in FEV, = airway sensitivity), and 
if possible, by their EC,, (concentration of methacholine that produced 50% of the maximal response=position) and 
level of plateau. 
The proportion of subjects with plateau was significantly lower in asthmatics (18.7%) than in either allergic 
rhinitics (57.3%) or healthy subjects (92%). It was also significantly lower in allergic rhinitics than in healthy subjects. 
The level of plateau for asthmatics was (means f SD) 31.5 f 5.5%, compared with 20.8 f 8.1% in allergic rhinitics 
and 13.7 + 6.7% in healthy subjects (P~0.01). It was also higher in allergic rhinitics than in healthy subjects 
(P~0.01). The EC,, values were decreased in asthmatics when they were compared with either allergic rhinitics or 
healthy subjects (geometric mean EC,,: asthmatics= 2.7 mg ml - ‘, allergic rhinitics=6.2 mg ml - ‘, healthy 
subjects = 8.7 mg ml ~ I; P<O.Ol), but no significant differences were detected between allergic rhinitics and healthy 
subjects. 
These results demonstrate that in subjects with allergic rhinitis, the prevalence and level of the plateau on the 
methacholine concentration-response curve is intermediate between that of asthmatics and normals. Furthermore, 
while the asthmatic curves differ from normal in having both an increased maximal response and a leftward shift, the 
rhinitic curves differ only in terms of plateau level. These results suggest that airway responsiveness in asthma and 
allergic rhinitis may be a consequence of mechanisms that are at least partially different. 
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Introduction 
Airway hyper-responsiveness can be defined as an increase 
above normal in both the ease and magnitude of airway 
narrowing on exposure to a number of non-sensitizing 
bronchoconstrictive stimuli (1,2). The abnormal airway 
responsiveness in asthmatics can be studied by constructing 
concentration-response curves to pharmacological bron- 
choconstrictors. Several methods for the analysis of the 
concentration-response curves have been developed, but 
the most commonly employed is the measurement of the 
concentration or dose that produces a pre-determined 
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response, such as the PC,, or PD,, (airway sensitivity). 
However, this measure does not assess excessive broncho- 
constriction. The presence and level of the maximal 
response plateau provides relevant information on the 
potential severity of airway obstruction (3,4). An absent or 
elevated maximal response plateau is an indication of 
excessive airway narrowing. Further, to define accurately 
the position of the concentration-response curve with 
respect to the x axis, a complete curve must be obtained (5). 
Thus, a plateau response must be achieved so that an EC,, 
value can be assigned. Previous studies have shown that 
after inhaling pharmacological agents, such as histamine 
and methacholine, non-asthmatic subjects may experience 
airway narrowing that is limited at some point (plateau) 
where no further constriction occurs even if the concen- 
trations of bronchoconstrictor are increased (2,6-g). By 
contrast, subjects with asthma do not generally demon- 
strate a plateau response, even with very severe degrees of 
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airway obstruction (2). Furthermore, it is now clear from a 
number of reports that non-asthmatic subjects with allergic 
rhinitis have a degree of airway sensitivity intermediate 
between that of healthy non-atopic persons and that of 
asthmatics (9-ll), but data on differences in the shape of 
the concentration-response curve between asthmatics and 
subjects with allergic rhinitis are scanty (6). 
There is accumulating evidence that airway inflammation 
is associated with the presence of airway hyper- 
responsiveness in subjects with asthma (12,13), but the 
critical features which determine airway hyper- 
responsiveness in subjects with allergic rhinitis are not yet 
determined. In a previous study, the authors have shown 
that, in subjects with seasonal allergic rhinitis, the maximal 
response plateau to methacholine can be modified by 
natural allergen exposure without changing the position 
(14). The present study tested the hypothesis that airway 
hyper-responsiveness in asthma is different to that in 
allergic rhinitis. To this end, the authors investigated differ- 
ences in sensitivity, position and maximal response plateau 
to methacholine between mild asthmatics, subjects with 
allergic rhinitis and healthy volunteers. 
Subjects and Methods 
SUBJECTS 
In total, 228 adults were studied: 107 patients with mild 
allergic asthma; 96 subjects with allergic rhinitis; and 25 
healthy non-atopic subjects. Asthmatic and allergic rhi- 
nitis patients were selected from the authors’ outpatient 
Allergy Clinic, whereas healthy subjects were recruited 
from volunteers in the laboratory and among students. 
Asthmatics and subjects with allergic rhinitis were selected 
to include a similar number of subjects sensitized to 
perennial and seasonal allergens. Subjects aged 18-60 
years were eligible for the study. All 228 subjects were 
life-long non-smokers, and none had history of chronic 
bronchitis, emphysema or respiratory tract infections dur- 
ing the 4 weeks before the study. Each patient was 
required to have a FEV, of at least 80% of the predicted 
value. Current or ex-smokers, pregnant women, and 
patients with significant renal, hepatic or cardiovascular 
disease were specifically excluded. 
Asthmatic subjects were defined as those individuals with 
a history of asthma (variable wheeze, dyspnoea, chest 
tightness or cough) and who also had at least one of the 
following criteria: an increase in FEV, of at least 15% after 
bronchodilator, or a positive methacholine challenge test, 
defined as a PC,, < 8 mg ml - i. The subjects had not used 
corticosteroids (oral or inhaled), theophyllines, sodium 
cromoglycate, nedocrdmil sodium, salmeterol or formot- 
erol for at least 6 months preceding the study. Symptoms of 
asthma were stable and controlled by the use on demand 
of inhaled salbutamol only. 
Subjects with allergic rhinitis were defined as those 
individuals with a characteristic history of perennial or 
seasonal allergic rhinitis (rhinorrea, sneezing, obstruction 
and pruritus) and who also have skin sensitization to 
perennial or seasonal allergens. No subject had a present or 
past history of asthma (wheezing, dyspnoea, chest tightness, 
chronic cough, or exercise wheeze). 
Healthy subjects had no history of asthma, allergic 
rhinitis, atopic eczema or other relevant disease, and were 
receiving no medication. All were non-atopics as defined by 
a skin wheal response ~3 mm in the presence of negative 
saline and positive histamine controls on skin-prick testing 
with common inhalant allergens. 
The study protocol was approved by the Medical Ethics 
Committee of the authors’ hospital, and informed consent 
was obtained from all participants. 
STUDY DESIGN 
Asthmatic and allergic rhinitis subjects with only seasonal 
symptoms were studied during a period of natural pollen 
exposure (May-July), whereas those with perennial symp- 
toms were studied during a period of maximal exposure to 
mites (October-December). 
On a screening day prior to the study, the inclusion and 
exclusion criteria were examined, written consent was 
obtained after full explanation and baseline spirometry 
and skin-prick tests were performed. At a second visit 
(l-30 days after initial evaluation), the high-concentration 
methacholine challenge was performed. 
SKIN PRICK TESTS 
In asthmatics and subjects with allergic rhinitis, atopic 
status was measured by skin prick tests using 13 common 
allergens applied to the forearm. The allergens (ALK- 
Abello, Madrid, Spain) tested were house dust mites 
(Deumatophagoides pteronyssinus and Devmatophagoides 
farinae), household pets (cat and dog), pollens (mixed 
grass, olive, Parietavia judaica, Platanus ovientalis, mixed 
weed), and moulds (Aternaria, Aspergillus fumigatus, 
Cladosporium and Penicillium). Histamine and glyceri- 
nated saline were used as positive and negative controls, In 
healthy subjects, skin-prick testing was performed with the 
six most common aeroallergens found in the Valencia area 
(D. ptevonyssinus, mixed grass, olive, Parietaria judaica and 
cat and dog dander). After 20 min, wheal size was recorded 
as the long axis and its perpendicular. A skin-test response 
was regarded as positive if the wheal was 3 mm greater in 
diameter than that of the glycerinated saline. 
PULMONARY FUNCTION TEST 
Pulmonary function measurements were carried out with a 
calibrated dry rolling seal spirometer (2130, Sensormedics 
Co., Yorba Linda, CA, U.S.A.). Forced expiratory 
manoeuvres (15) were repeated until three measurements of 
FEV, reproducible to 100 ml were obtained, of which the 
larger FEV, value was used in analyses. Reference values 
are those of the European Community for Coal and 
Steel (16). 
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TABLE 1. Subjects, characteristics and pulmonary function data 
Asthma Allergic rhinitis Healthy 
Number 107 96 25 
Age (years)* 31.1* 11.5 30.7 rt 10.7 32.6 zt 8.6 
Male/female 49158 46150 8/17 
Perennial/seasonal 61146 49147 - 
Duration of symptoms (years)* 10.5 ZIZ 6.4 9.8 h 6.9 - 
FEV, (% predicted)* 97.7 * IO.3 110.4 5 12.1 112.9 f 9.9 
FEVJFVC %* 80.8 zk 6.8 84.5 zt 6.7 87.4 f 5.5 
FEV,, forced expiratory volume in 1 s; FVC, forced vital capacity. *Data presented as mean + SD. 
HIGH-CONCENTRATION METHACHOLINE 
CHALLENGE 
Before methacholine challenge, patients discontinued 
their treatment for at least 12 h (inhaled short-acting 
&agonists), 4 weeks (nasal topical corticosteroids and 
nasal topical cromoglycate) and 3 days (antihistamines). 
Methacholine airway responsiveness was assessed using 
a modification (17) of the tidal breathing method (9). 
Aerosols were generated with a Hudson 1720 nebulizer 
(Temecula, CA, U.S.A.) calibrated to deliver an output of 
0.17 ml min- I. Aerosols were inhaled for 2-min periods 
of quiet tidal breathing. After inhalation of phosphate- 
buffered saline, methacholine (Sigma Chemicals, St. Louis, 
MO, U.S.A.) was administered in doubling concentrations. 
The starting concentrations of methacholine were 0.39 mg 
ml-’ for healthy subjects or patients with allergic rhinitis, 
and 0.095 mg ml- ’ for asthmatic patients. Due to the effect 
of a deep inspiration on subsequent airway tone (18), only 
one measurement for FEV, was performed 60-90 s after 
inhalation of each concentration unless the forced expira- 
tory manoeuvre was judged to be technically unsatisfactory. 
The test was interrupted when FEV, dropped by more than 
40% or when the highest concentration of methacholine 
(200 mg ml - ‘) had been administered. Salbutamol aerosol 
was administered to aid recovery when necessary. 
Concentration-response curves were plotted for each 
challenge test as percentage fall in FEV, against the log 
methacholine concentration and were Fharacterized by their 
sensitivity (concentration of methacholine that produced a 
20% fall in FEV,, PC,,) and, if possible, by their position 
(concentration of methacholine that produced 50% of the 
maximal response, EC,,) and maximal response plateau 
level. 
DATA ANALYSIS 
The sample size requirements of this study were calculated 
to compensate for differences in the prevalence of plateau 
between asthmatics and non-asthmatic subjects (7,19). The 
authors defined a difference’of 7% in the level of plateau as 
clinically relevant. Based on a calculated SD of 7.5% for the 
level of plateau from previous studies (19,20), it was esti- 
mated that 19 patients with plateau in each group would be 
required to provide 80% power at the two-sided 0.05 level. 
Methacholine PC,, was calculated from the log 
concentration-response curves by linear interpolation of the 
two adjacent data points. A PC,, value of 200 mg ml- ’ 
was assigned to 23 patients with allergic rhinitis and to 17 
healthy subjects in whom FEV, dropped less than 20% even 
when the highest concentration of methacholine was used. 
A plateau response was considered to be present when, for 
three or more of the highest concentrations of metha- 
choline, the FEV, did not change by more than 5%. The 
level of the maximal response was obtained by averaging 
the data points on the plateau (7). In the absence of a 
plateau, the largest fall in FEV, was documented and not 
considered for analysis. The position of the concentration- 
response curve in subjects with plateau was assessed by 
EC,,, which was obtained by interpolation. All PC,, and 
EC,, values were log-transformed before analysis. 
Skewedness of distributions was assessed with 
Kolmogorov-Smirnov tests and a P value >0.05 was 
obtained. Thus, unpaired Student’s t test or one-way analy- 
sis of variance (ANOVA) were used to compare group 
means. When a significant F-test for a variable was 
obtained, a Newman-Keuls’ multiple range test was carried 
out. Categorical variables were analysed with the Fisher’s 
exact test. The null hypothesis was rejected at PcO.05. 
Results are expressed as mean Z!C SD unless otherwise 
indicated. 
Results 
The clinical and pulmonary function data at baseline 
for asthmatics, subjects with allergic rhinitis and healthy 
volunteers are presented in Table 1. The three groups did 
not differ with respect to age and sex. Moreover, asthmatic 
and allergic rhinitis patients did not differ with respect to 
duration of symptoms and prevalence of skin sensitization 
to perennial or seasonal allergens. The mean lung function 
value (FEV, and FEV,/FVC%) for the group with asthma 
was significantly lower (P<O.OOl) than the mean value for 
the allergic rhinitis subjects and the healthy individuals, but 
there were no significant differences between subjects with 
allergic rhinitis and healthy volunteers. 
The geometric mean PC,, value for asthmatic patients 
(Table 2) was 0.8 mg ml - ‘, compared with 14.1 mg ml - ’ 
(P<O.Ol) in subjects with allergic rhinitis and 93.3 mg ml - ’ 
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TABLE 2. Methacholine responsiveness in asthmatics, subjects with allergic rhinitis and healthy 
individuals 
Asthma Allergic rhinitis Healthy 
PGo (ms ml - ‘It 
Plateau (yes/no) 
Level of plateau (% FEVJ* 
EC,, Om ml - ‘1 t 
0.8 (0.1-17.4) 14.1 (0.4-200.0) 93.3 (1.2-200.0) 
20/87 55141 2312 
31.5 & 5.5 20.8 i- 8.1 13.7 =k 6.7 
2.7 (0.3-36.3) 6.2 (0.840.7) 8.7 (1.3-84.2) 
PC,,, concentration of methacholine that causes a 20% fall in FEV,; FEV,, forced expiratory 
volume in 1 s; level of plateau, average of the data points on the plateau in subjects in whom plateau 
was detected; EC,,, concentration of methacholine that produced 50% of the maximal response in 
subjects with plateau. *Data presented as mean f SD, tdata presented as geometric mean and range 
in parentheses. 
: 
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Asthma Allergic rhinitis Healthy 
FIG. 1. Individual values for level of plateau in asthmatics 
(n=20), allergic rhinitics (n= 55) and healthy subjects 
(n=23$ in whom plateau was detected. Horizontal lines 
are means. 
(PcO.01) in healthy subjects. The PC,, was also signifi- 
cantly lower in subjects with allergic rhinitis than in healthy 
individuals (PcO.01). 
The proportion of subjects with plateau (Table 2) was 
lower (P<O.OOl) in asthmatics (18.7%) than in either 
allergic rhinitics (57.3%) or healthy subjects (92%). Subjects 
with allergic rhinitis also had a lower prevalence of plateau 
than healthy subjects (P<O.OOl). The level of plateau for 
asthmatics (Table 2, Fig. 1) was 31.5 i 5.5%, compared 
with 20.8 i 8.1% in subjects with allergic rhinitis (P<O.Ol) 
and 13.7 f 6.7% in healthy subjects (WO.01). The level of 
plateau was also significantly higher in allergic rhinitics 
than in healthy subjects (P<O.Ol). 
The EC,, values (Table 2, Fig. 2) were significantly 
decreased in the subjects with asthma when they were 
compared with either allergic rhinitics or healthy subjects 
(P<O.Ol). No significant differences were detected between 
patients with allergic rhinitis and healthy subjects. 
Asthma Allergic rhinitis Healthy 
FIG. 2. Individual values for EC,, in asthmatics, allergic 
rhinitics and healthy subjects with plateau. Horizontal 
lines are geometric means. EC,,, concentration of 
methacholine that produced 50% of the maximal 
response. 
Discussion 
This study found differences in the PC,, (sensitivity), EC,, 
(position) and maximal response plateau to inhaled metha- 
choline between mild asthmatics, subjects with allergic 
rhinitis and healthy individuals. Comparison of 
concentration-response curves showed that mild asthmatics 
have not only higher airway sensitivity, but also lower 
prevalence and higher level of plateau than non-asthmatics. 
Subjects with allergic rhinitis have values for sensitivity and 
for the maximal response that were intermediate to those 
detected in healthy subjects and mild asthmatics. Further- 
more, a leftward shift of the curve (decreased EC,,) 
was detected in asthmatics when compared with non- 
asthmatics, but no differences were detected between 
patients with allergic rhinitis and healthy subjects. 
There are some important methodological problems 
in this study. Estimation of the airway sensitivity was 
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complicated because 23 (24%) patients with allergic rhinitis 
and 17 (68%) healthy subjects had PC,, values above the 
upper limit of measurement. A PC,, value of 200 mg ml- ’ 
was assigned to these subjects, but this gives an underesti- 
mation of their true PC,, value. Another major methodo- 
logical problem encountered was the difficulty for analysis 
of all in vivo concentration-response curves. Complete 
curves were obtained in only 98 (43%) subjects. Obviously, 
the position and maximal response in subjects without a 
plateau are not known. 
The subjects were tested during a period of maximal 
natural allergenic exposure, and previous studies have 
demonstrated that natural allergenic exposure causes the 
loss of plateau in a significant number of subjects with 
asthma (17,20) or allergic rhinitis (14). This may explain the 
high prevalence of asthmatics and allergic rhinitics without 
evidence of plateau in this study. Furthermore, one could 
argue that a proportion of subjects who showed FEV, falls 
>40% without evidence of plateau might have plateau 
beyond a 40% fall from baseline FEV,. The degree of 
airway narrowing induced in this study was similar to that 
in other reports (6,21), but it is possible that some of our 
subjects without evidence of plateau might have plateau at 
a greater degree of obstruction. 
It has long been recognized that patients with asthma 
generally exhibit hypersensitivity to pharmacological 
agonists (9,22), but the shape of the concentration-response 
curve in asthmatic and non-asthmatic subjects has been 
examined more recently. Even in subjects with mild asthma, 
the maximal response plateau to methacholine is raised or 
is immeasurably higher (2,17). On the contrary, non- 
asthmatic subjects show a maximal response at a relatively 
mild degree of airway narrowing (2,7,8). Although the level 
of plateau is highly variable among non-asthmatic subjects, 
it generally occurs before FEV, is decreased by 40% (8,23). 
In keeping with previous studies (2,8,24), the present 
authors have detected a lower prevalence of plateau in 
asthmatics than in non-asthmatic subjects. Indeed, in these 
subjects in whom plateau was detected, the level of the 
maximal response was significantly higher in asthmatics 
than in non-asthmatics. This finding appears to differ from 
that of James et al. (8) who found no difference in the level 
of plateau between subjects reporting asthma or wheeze and 
non-asthmatics. This difference in results may be related to 
a variety of factors including challenge methods and popu- 
lation differences. The degree of induced airway constric- 
tion was greater in the study of James et al. (8) since the 
test was stopped when the FEV, fell by >50%. Moreover, 
in the study of James et al. (8) the FEV, was measured 30 
and 90 s after each methacholine dose, whereas in the 
present study, a single spirometry *as performed after each 
concentration. 
It is now clear from a number of studies that an increased 
sensitivity to pharmacological agonists, such as histamine 
,or methacholine, is a common feature in subjects with 
allergic rhinitis (9-l 1). Several reports have indicated that 
subjects with allergic rhinitis have a degree of airway 
sensitivity to inhaled pharmacological bronchoconstrictors 
intermediate between that of healthy non-atopic persons 
and that of asthmatics (g-11). However, data on differences 
in the level of plateau are scanty. Townley et al. (6) 
measured airway responsiveness to methacholine in 27 
non-asthmatic individuals with allergic rhinitis. These 
authors reported that an appreciable number of subjects 
showed a maximal response plateau at mild degrees of 
airway narrowing. A maximal response plateau was 
detected in 57% of study patients with allergic rhinitis. This 
agrees with data from a recently published study (19). 
To the best of the authors’ knowledge, no previous 
information is available on differences in the prevalence and 
level of plateau between non-asthmatic subjects with 
allergic rhinitis and healthy non-atopic individuals. In the 
present study, allergic rhinitics were found to have lower 
prevalence and higher level of plateau than healthy subjects. 
Furthermore, they had higher prevalence and lower level of 
plateau than mild asthmatics. Thus, subjects with allergic 
rhinitis were found to have values for the shape of the 
concentration-response curve that were intermediate to 
those detected in normal subjects and mild asthmatics. 
This is the first study to document differences in the 
position of concentration-response curve between asth- 
matics, patients with allergic rhinitis and healthy non- 
atopic subjects. Compared with non-asthmatic subjects, the 
concentration-response curve in patients with asthma was 
shifted to the left. However, the values of EC,, were similar 
in allergic rhinitics and healthy subjects, indicating no 
differences in the position of the concentration-response 
curves. The present finding of an increased maximal 
response with a leftward shift of the concentration- 
response curve in subjects with asthma are suggestive of a 
concomitant pre-junctional and post-junctional mechanism 
of increased responsiveness (4). On the contrary, the present 
findings of an increased maximal response without a shift 
in concentration-response curve in subjects with allergic 
rhinitis are suggestive of a post-junctional mechanism of 
increased responsiveness (5). 
The present observations are relevant to understand the 
mechanisms of airway hyper-responsiveness in asthma and 
allergic rhinitis. There is some evidence that the mech- 
anisms underlying the position and the maximal response 
are at least partially different (4,5). Recent studies indicate 
that maximal airway narrowing is selectively dependent on 
swelling of the airway wall (accumulation of oedema or 
connective tissue), either internal or external to the smooth 
muscle layer (25,26). Inflammatory processes have been 
associated with the presence of airway hyper-responsiveness 
in subjects with asthma (12,13), but the critical features 
which determine airway hyper-responsiveness in subjects 
with allergic rhinitis are not yet determined. It is not known 
whether in subjects with allergic rhinitis, the increased 
airway responsiveness is associated with airway inflam- 
mation (27) or if it is linked to other mechanisms (28,29). 
The lack of effect on airway sensitivity of inhaled corti- 
costeroids in subjects with allergic rhinitis has been inter- 
preted as experimental evidence against the presence of 
structural changes in the airways(28). However, it has been 
shown that the maximal response plateau to methacholine 
can be altered by inhaled budesonide without changing the 
sensitivity (30) and that the sensitivity can be altered 
without changing the maximal response (20). The results of 
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the present study are suggestive of a post-junctional mech- 
anism of increased responsiveness in subjects with allergic 
rhinitis, and a likely candidate for this mechanism is the 
swelling of the airway wall. Recently, Boulet et al. (31) were 
not able to show a significant increase in large airway wall 
thickness of subjects with seasonal allergic rhinitis during 
natural allergen exposure. As suggested by these authors, 
this could indicate that the small airways are more import- 
ant in determining the responses to allergen exposure. 
Whatever the mechanism, consideration of the origin of 
airway responsiveness must take into account the reason 
for differences in maximal response and position of the 
concentration-response curve between asthmatics and 
subjects with allergic rhinitis. 
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